Replies to post #53909 on CV Sciences Inc (CVSI)

[jefra1965]

If Cwbhf has over 6000 retail stores and generates 50 percent of their sales from online and CVSI has close to 5000 retail stores and only 15.7 percent online sales. It appears that CVSI is doing better in sales of products in stores than Cweb. Cwbhf is spending 4 million more dollars on advertising, marketing, General, and administrative areas of their business. If CVSI is doing better in stores, then it is possible that CVSI can bypass them in total sales. With over 100’s of fly by nights selling on the internet, it will saturate that part of the market. Being in stores will allow Cvsi to continue to be one of the leaders in the cbd market.
Imo Wolf


Breakdown of R&D Selling/Marketing , General, Administrative Costs. Comparison/Contrast with CVSI quarters and CWBHF R&D And GASM costs.

Q1 2019 R&D $1,342,000
Q2 2019 R&D. $1,688,000
Total........$3,030,000

This is amazing. The company is serious about their Scientific side of the equation you understand.

CWBHF Q1 2019 $191,000 Q1 2018 $126,000.

Selling, General, Administrative costs

Q1 2019 $18,595,000
Q2 2019 $. 9,009,000
Total SG&A Q1 & Q2 $27,604,000

SGA is averaging around $9 million per quarter. I believe Q1 included Mona’s 9 million payday.

General, Administration, Selling, & Marketing

CWBHF Q1 2019 G&A $8,461,000.Q1 2018 $4,066,000.
CWBHF Q1 2019 S&M $4,560,000.Q1 2018 $2,063,000
Total GASM Q1 2019 & $13,021,000



CWBHF is spending $4 million more on GASM than CVSI. This is considered an investment in the short run.

CVSI is spending around 1.2 million more on R&D. This cost is considered an investment for the long run.

Plain an simple deduction.

Also, the new and huge exposure that CVSI will get at the FDMs will promote direct online sales with better discounts for the costumers and better margins for the company's top line. Costumers will be able to talk to the clerks about the quality, compare prices. Products with isolates will not exist in the FDMs.

Then if CWEB is forced to go FSHE by the USDA issuing a specific list of cultivars from where to produce Industrial (NOT botanical) FSHE CBD, then spider will be left with NO specialized technology to produce a similar HQ FSHE as PlusCBD.

But this is all me speculating here, wondering about which company is at the most risk going forward. You understand.

[super_trades]

Wolf, CVSI R&D is split between development of their nicotine drug and their CBD segment. Page 16 of the 10Q. So 600k on CBD R&D is something not much at all.

Research and development (“R&D”) expense increased to $1.7 million in the second quarter of 2019 compared to $0.4 million in the second quarter of 2018. The increase of $1.3 million or 282% is related to additional R&D expenses for our specialty pharmaceutical segment of $0.7 million and for our consumer products segment of $0.6 million. The increase in our specialty pharmaceutical segment is mostly related to preclinical work, development cost associated with our active pharmaceutical ingredient ("API"), and expenses paid to outside consultants. The additional R&D expense in our consumer products segment is mostly related to additional personnel cost, cost for clinical trials, and cost for outside services for our new consumer product developments.